to RAASI and treatment of HK remains subspecialty and rarely used. This real-world study describes treatment patterns in patients with CKD and HK across geographies.

**Methods:** The cohort was extracted from: Japan Medical Data Vision (JMDV), Clinical Practice Research Datalink (CPRD), and integrated Limited Claims and Electronic Health Record (iCERD) data. Patients with HK (two sK+ measures >5.0 mmol/L aged >18 years (≥20 years for JMDV) with a diagnostic CKD code (stage 3A-5 including renal replacement therapy) or two estimated glomerular filtration rate (eGFR) measures <75 mL/min/1.73m² at least 90 days apart between January 2008 and October 2018 were included. For patients with eGRFs 60-75 mL/min/1.73m² there was one more of the following ICD-10 code(s) required: hypertension, glomerulonephritis, lupus nephritis, ANCA nephritis, or polycystic kidney disease. Index was 2nd HK event. We describe the median number of days and percentage of time on treatment during follow-up by HK severity at index for treatments commonly prescribed to patients with CKD that may impact sK+ levels (e.g. RAASI), and for HK including: K+ binders or emergency dialysis (ED). We also describe characteristics of patients treated with K+ binders.

**Results:** A cohort of 46,030 patients with CKD and HK were identified, of which 35,362 (4,536, 29,009, and 1,817 from Japan, UK and US, respectively) were prescribed treatments that may impact sK+ levels and for HK during follow-up. Mean (SD) age was 78.1 (11.7), 74.0 (11.4) and 73.4 (12.4) years and 49%, 50% and 50% were female from Japan, UK and US, respectively. Over a third of patients were not taking RAASI during follow-up. For those who were taking RAASI, as index HK severity increased, the median number of days and percentage of time on RAASI decreased across all countries, Table 1. Therapies specific to treating HK included 4% of patients taking K+ binders with the majority (85%) of use in Japan. Use of ED was negligible across databases. Median (IQR) sK+ at initiation of K+ binders was 5.7 (5.3-6.0), 6.0 (5.6-6.3) and 3.6 (5.2-5.9) mmol/L for Japan, UK and US, respectively. Median time on K+ binders reflected more acute use in the UK and US vs more chronic use in Japan, Table 1.

**Conclusions:** In this CKD population with HK, increased HK severity and management of HK across geographies varied. Therapies specific for treating HK were scarcely used and mostly initiated when HK was moderate to severe (>5.5). These findings suggest that effective and well-tolerated treatments that treat HK and allow continuation of RAASI therapy may be beneficial. Future studies are warranted to explore the association of whether treatments for HK allow continuation of RAASI therapy.

**Conflict of Interest:** GJ, SK, EW, and KH are employees of and stockholders of AstraZeneca. JJC has received institutional grants from AstraZeneca, Vifor Pharma and Astellas speaker fees from AstraZeneca, Abbott and Novo Nordisk consultancy for AstraZeneca, Baxter Healthcare and Vifor Pharma, respectively. SC has received research and consulting fees from AstraZeneca research support from Akebia Inc, MegaPro Biomedical Co., Ltd, Aradelx, Cordivia Therapeutics, and Cara Therapeutics. KJ is a consultant for AstraZeneca. NS is a consultant for AstraZeneca, Boehringer Ingelheim, Kyowa Hakko Kirin and receives honoraria from Nippon Boehringer, Daiichi Sankyo and Sanofi. SA has received research grants from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck (Diabetes), Novo Nordisk, Sanofi, Vifor Pharma receives honoraria from AstraZeneca, Boehringer Ingelheim, Novo Nordisk and other research support from AstraZeneca. MD has received personal fees, travel, accommodations, meals and accommodations from research grants from Roche Diagnostics has served as consultant or on the Advisory Board/ Steering Committee for AstraZeneca, Boehringer Ingelheim, Novartis, Vifor Pharma has received personal fees from Abbott, Agena, AstraZeneca, Boehringer Ingelheim, Novartis, Sanofi, Servier, Vifor Pharma. CSPL is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore has received research support from Boston Scientific, Bayer, Roche Diagnostics, AstraZeneca, Medtronic, and Vifor Pharma has served as consultant or on the Advisory Board/ Steering Committee/ Executive Committee for Abbott Diagnostics, Agena, Applied Therapeutics, AstraZeneca, Bayer, Biofourm, Boehringer Ingelheim, Boston Scientific, Corvia Medical, Cytokinetics, DaMar Inc, Eko.ai Pte Ltd, JanaCare, Janssen Research Development LLC, Medtronic, Merck KGaA, Merck, Myokardia, Novartis, Novo Nordisk, RadiCure Group Ltd., Roche Diagnostics, Sanofi, Stealth BioTherapeutics, The Corpush, Vifor Pharma and WebMD Global LLC and serves as co-founder & non-executive director of Us2.ai Pte Ltd. CP has Advisory Board membership with AstraZeneca, Vifor, Eli Lilly/ Boehringer Ingelheim, Speaker fees Novartis, Janssen Cilag, Otsuka, Astra Zeneca, Vifor. PS is on Advisory Boards of Astra Zeneca, Baxter, REATA, Vifor, FMC, and Astellas. DCW has received personal fees and non-financial support from AstraZeneca, as well as personal fees from Bayer, Boehringer Ingelheim, Astellas, GlaxoSmithKline, Janssen, Napp, Mundipharma, Reata, Vifor Fresenius, and Tricida. RR-P is an employee of and shareholder for Arbor Research Collaborative for Health and receives global support for the ongoing DOPPS Programs (provided without restriction on publications by a variety of funders - for details see https://www.dopps.org/AboutUs/Support.aspx). He also reports research grants from Fresenius Medical Care, non-financial support from Astra Zeneca, Bayer, Boehringer Nordisk, Akebia, and personal fees from Retrophin outside the submitted work.

**POS-330**

**RISK PERCEPTIONS ABOUT COVID-19 AMONG A COHORT OF CHRONIC KIDNEY DISEASE PATIENTS IN RURAL INDIA**

John MD, Q1,2,3, Gummidi, B1, Jha, V1,2,3

1The George Institute for Global Health, Better Treatments-Renal and Cardio Metabolic, New Delhi, India; 2Manipal Academy of Higher Education, Prasanna School of Public Health, Manipal, India, 3University of New South Wales, Faculty of Medicine, Sydney, Australia

**Introduction:** COVID-19 pandemic has resulted in disruption to routine health services delivery as strict lockdowns were implemented in India. The nation-wide lockdown lasting 2 months was imposed with an aim to reduce the spread of infection and prepare the health systems capacity for the pandemic. The Government of India issued advisory for those with chronic conditions to avoid visits to healthcare facilities for non-emergency consultations. The ‘Study to Test and Operationalize Preventive Measures’ approaches for chronic kidney disease (CKD) of the STOP COVID-19 (SToptreatment of (CKD) (STOP CKDu) is following up a community-based cohort of 2419 participants over the age of 18 years in 40 clusters (75 villages) of Srikakulam District in Andhra Pradesh, India since Feb 2018. We conducted this mixed methods study to assess the risk perception of participants in our cohort about COVID19 and understand the impact of COVID and the mobility restrictions posed by lockdown on the access to care and compliance to treatment among the adults with CKD.

**Methods:** We administered a structured questionnaire and undertook qualitative interviews to address the study objectives. Seven questions were added to the STOP CKDu study follow up to determine the level of awareness and risk perceptions regarding COVID-19 and compliance to ongoing treatment schemes. All responses were recorded through an electronic data collection tool and statistical analysis performed.

**Results:** 2419 participants were followed up since May 2018 in the STOP CKDu cohort, 2276 participated in current telephonic survey (40 had died, 85 migrated and 18 could not be contacted). The mean age was 45.8 (±13.3) years, and half were women. With respect to risk perceptions, 77% (±1.5) of COVID-19 was perceived as moderate to severe, 68% participants exhibited good knowledge of the common symptoms and prevention measures. However, 43% were not aware of the mode of disease transmission. Our participants a high risk group due to NCDS/ CKD, were aware of public health measures (social/ physical distancing, lockdown and usage of masks or face covering). Out of 822 respondents, who were scheduled to have a medical follow up, 115 (14%) missed their follow up visit during the lockdown, 110 (13.4%) reported facing challenges in medication procurement and 98 (11.6%) either developed new symptoms or experienced worsening of
pre-existing symptoms. 233 (28.5%) used telemedicine facility and sought telephonic advice from (private) physicians, while 149 (18.2%) were able to undertake an in-person visit to their regular healthcare provider. Among those with ESKD, seven subjects were undergoing regular in-centre haemodialysis. Four of them reported missing their scheduled sessions. One developed severe breathlessness and died despite receiving dialysis.

**Conclusions:** This is the first study conducted in India to assess the effect of the ongoing COVID-19 pandemic on risk perceptions and access to health services for persons with CKD. Our findings provide insights into the risk perceptions, and practices prevailing in a high CKD burden setting in rural India. We highlight the urgent need for comprehensive guidelines that address continuum of care for NCDs/CKD during the current and future disruptions to routine healthcare service delivery. Prioritization by governments to ensure uninterrupted essential primary healthcare services would be key to preparing for future pandemics.

**Conflict of Interest:** STOP CKDu study is funded by the Government of Andhra Pradesh under a grand challenges research programme in partnership with Indian Council of Medical Research.

**POS-331**

**ASSOCIATION OF IMPAIRED KIDNEY FUNCTION WITH MORTALITY IN RURAL UGANDA: RESULTS OF A GENERAL POPULATION COHORT STUDY**

Kalyesubula, R*1, Sekitoleko, I2, Tomlin, K3, Hansen, C4, Ssebunya, B5, Makanga, R6, Hughes, P7, Kwizera Mbonye, M7, Seeley, J8, Liam, S1, Robert, N9, A Tomlinson, L1

1 London School of Hygiene and Tropical Medicine, Non Communicable Disease Epidemiology, London, United Kingdom; 2MRC/LUVR & LSHTM Research Unit, Non Communicable Diseases, Entebbe, Uganda; 3London School of Hygiene and Tropical Medicine, Epidemiology, London, United Kingdom; 4London School of Hygiene and Tropical Medicine, Biostatistics, London, United Kingdom; 5MRC/LUVR & LSHTM Research Unit, Non Communicable Disease, Entebbe, Uganda; 6MRC/LUVR & LSHTM Research Unit, Biostatistics, Entebbe, Uganda; 7MRC/LUVR & LSHTM Research Unit, Laboratory, Entebbe, Uganda; 8London School of Hygiene and Tropical Medicine, Social Sciences, London, United Kingdom; 9University of York, Epidemiology, York, United Kingdom

**Introduction:** The burden of kidney disease in sub-Saharan Africa is currently poorly understood. Very limited monitoring and treatment is available for people affected. The association with other diseases and with mortality is unknown in this setting. We sought to determine the association between kidney function and subsequent all-cause mortality.

**Methods:** In a general population cohort with detailed measurement of glomerular filtration rate (GFR) between 2011-2014 in 5,678 participants. We followed participants up to March 2019 with regular ascertainment of mortality and migration. Using multivariable cox regression, we determined associations between baseline eGFR and mortality.

**Results:** The median age of the participants at baseline was 36 years (IQR 24-50), 60.7% were female, 14.6% hypertensive, 9.7% HIV-positive and 1.8% diabetic. We registered 140 deaths with a median follow-up of 5.0 years. Adjusting for age and sex, HIV, hypertension, diabetes, BMI, marital status, and alcohol and tobacco use participants with eGFR ≤45 mls/min/1.73m² had six-fold higher mortality compared to those with eGFR ≥60mls/min/1.73m² (HR 6.12 (95% CI 2.27-16.45)) with strong evidence of a linear trend for risk of mortality as renal function declined (P<0.001).

**Conclusions:** In a prospective cohort with high rates of follow-up we found that baseline kidney function was associated with subsequently increased mortality in a graded manner. Improved understanding of the determinants of kidney disease and its progression are needed in order to inform interventions for prevention and treatment.

No conflict of interest

**POS-333**

**THE INDIAN CHRONIC KIDNEY DISEASE STUDY: DETAILED DESCRIPTION OF BASELINE CHARACTERISTICS**

Kumar, V1, Sethi, J1, Yadav, AK2, Ghosh, A3, Kundu, M3, Jha, V3

1Postgraduate Institute of Medical Education and Research- Chandigarh- India, Nephrology, Chandigarh, India; 2Postgraduate Institute of Medical Education and Research- Chandigarh- India, Experimental Medicine and Biotechnology, Chandigarh, India; 3George Institute for Global Health-India-New Delhi, Nephrology, New Delhi, India

**Introduction:** The Indian Chronic Kidney Disease (CKD) study is an ongoing, nationwide, multicentric prospective cohort study recruiting participants with mild to moderate CKD that aims to identify risk factors for CKD development and progression and implement effective therapies. Here, we report the baseline socio demographic, etiology of CKD, risk factors and laboratory parameters in the inception cohort.

**Methods:** Patients with confirmed CKD between 18-70 years of age and estimated glomerular filtration rate (eGFR) of 15-60ml/min/1.73m² or eGFR >60ml/min/1.73m² and proteinuria/albuminuria with stable clinical course for at least 3 months have been recruited. Organ transplant recipients, those with malignancy for last 2 years, non-Indian ethnicity, pregnancy in case of females, on immunosuppressive therapy, life expectancy <1 year and with poor functional status are excluded. Socio-demographic details, history related to kidney diseases, traditional and indigenous risk factors, CVD and other co-morbidities are recorded. Blood and urine samples are being collected at baseline and annually. Primary outcome of the study is time to ESRD/RRT, 50% decline in eGFR and any new cardiovascular event

**Results:** Total 4056 CKD subjects has been enrolled. The mean age of the cohort was 50.3 +/-11.8 years with 67.2% males. Median eGFR was 45 mls/min/1.73m² had six-fold higher mortality compared to those with eGFR ≥90mls/min/1.73m² (HR 6.12 (95% CI 2.27-16.45)).

No conflict of interest